Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q3 2019 · 10-Q
Revenue$80.14M$80.14M+6.1% vs Q3 2018 Net Income$1.31M$1.31M−45.2% vs Q3 2018 EPS Diluted$0.03$0.03−40.0% vs Q3 2018 Gross Profit$35,252,000+20.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived-$12,003,000N/M Free Cash Flowderived-$20,681,000N/M Margins · derivedGross margin44.0%+5.3 pt vs Q3 2018
Operating margin3.0%−0.4 pt vs Q3 2018
Net margin1.6%−1.5 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 8, 2019 · 39 d after period end